Saitama Medical University International Medical Center
1 clinical trials · Sponsor
◉ Watch Saitama Medical University International Medical Center
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer (NCT04641728) | Saitama Medical University International Medical Center | 2021-01-01 |
Track Saitama Medical University International Medical Center automatically
Every clearance here is in the API, with alerts when new ones post.